Banook, a leading global provider of centralized cardiac safety, central imaging and clinical endpoint management services, today announced the acquisition of Fluidda, a pioneer in respiratory imaging and Functional Respiratory Imaging (FRI) technologies.
The acquisition marks a significant milestone in Banook’s strategy to diversify and expand into respiratory clinical research and advanced imaging analytics.
Founded in Belgium, Fluidda is recognized globally for its expertise in computational fluid dynamics and quantitative CT-based imaging to assess lung structure and function. Its proprietary Functional Respiratory Imaging (FRI) platform is widely used to optimize drug development and improve patient outcomes in chronic respiratory diseases such as asthma, COPD, interstitial lung disease (ILD), and pulmonary hypertension (PH).
By integrating Fluidda’s cutting-edge imaging capabilities with Banook’s operational excellence in endpoint management and global clinical trial delivery, the combined organization will offer an unmatched portfolio of scientific, imaging, and data-driven services across respiratory and cardiovascular therapeutic areas.
The acquisition comes at a time of strong growth in the respiratory clinical trial market, which is expanding at approximately 6–8% CAGR. Rising prevalence of chronic respiratory diseases and a surge in development of biologics, inhaled therapies, and smart respiratory devices are fueling demand for specialized imaging, data analytics, and centralized endpoint services. In 2024, the global market for respiratory clinical trial services – Including logistics, recruitment, and CRO support – was valued at over $3 billion, with projections exceeding $5 billion by 2030.
With this acquisition, Banook expands its geographic reach and technological offering, reinforcing its position as a global scientific partner of choice for pharmaceutical, biotech, and medical device companies. Fluidda will continue to operate under its brand as part of Banook, maintaining its R&D center in Belgium and Portugal while leveraging Banook’s global infrastructure and quality systems.
“This acquisition aligns perfectly with our vision to expand Banook’s scientific and technological capabilities across major therapeutic domains,” said Alexandre Durand-Salmon, Chief Executive Officer of Banook. “Fluidda’s innovative imaging technology and deep respiratory expertise will strengthen our ability to deliver high-quality, patient-centered solutions for complex global trials.”
Jan de Backer, Chief Executive Officer of Fluidda, added: “Joining Banook will accelerate the global adoption of our Functional Respiratory Imaging platform and enhance our impact on respiratory drug development. Together, we can offer sponsors integrated solutions that improve trial efficiency and patient outcomes.”
Following the acquisitions of Nabios (Germany, 2021), Keosys and B. Research (2024), Fluidda becomes Banook’s fourth acquisition, supporting its successful organic growth strategy, with an historical double digit growth rate.
Financial details of the transaction were not disclosed.
